Randall Stanicky
Stock Analyst at RBC Capital
(2.30)
# 2,510
Out of 4,728 analysts
32
Total ratings
60%
Success rate
5.18%
Average return
Main Sectors:
Stocks Rated by Randall Stanicky
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ABBV AbbVie | Maintains: Outperform | $129 → $135 | $175.55 | -23.10% | 10 | Feb 4, 2021 | |
| PRGO Perrigo Company | Downgrades: Sector Perform | $59 → $49 | $23.51 | +108.42% | 8 | Jan 6, 2021 | |
| PFE Pfizer | Downgrades: Sector Perform | $43 → $42 | $26.41 | +59.03% | 3 | Dec 16, 2020 | |
| JAZZ Jazz Pharmaceuticals | Maintains: Outperform | $170 → $180 | $122.96 | +46.39% | 2 | Nov 3, 2020 | |
| MRK Merck & Co. | Maintains: Sector Perform | $92 → $89 | $99.65 | -10.69% | 1 | Apr 1, 2020 | |
| AMRX Amneal Pharmaceuticals | Maintains: Sector Perform | $3 → $4 | $7.85 | -49.04% | 3 | Jan 2, 2020 | |
| OPTN OptiNose | Initiates: Outperform | $495 | $5.00 | +9,800.00% | 1 | Nov 7, 2017 | |
| TEVA Teva Pharmaceutical | Downgrades: Underperform | n/a | $20.98 | - | 3 | Aug 4, 2017 | |
| PCRX Pacira BioSciences | Initiates: Outperform | $58 | $20.55 | +182.24% | 1 | Apr 13, 2017 |
AbbVie
Feb 4, 2021
Maintains: Outperform
Price Target: $129 → $135
Current: $175.55
Upside: -23.10%
Perrigo Company
Jan 6, 2021
Downgrades: Sector Perform
Price Target: $59 → $49
Current: $23.51
Upside: +108.42%
Pfizer
Dec 16, 2020
Downgrades: Sector Perform
Price Target: $43 → $42
Current: $26.41
Upside: +59.03%
Jazz Pharmaceuticals
Nov 3, 2020
Maintains: Outperform
Price Target: $170 → $180
Current: $122.96
Upside: +46.39%
Merck & Co.
Apr 1, 2020
Maintains: Sector Perform
Price Target: $92 → $89
Current: $99.65
Upside: -10.69%
Amneal Pharmaceuticals
Jan 2, 2020
Maintains: Sector Perform
Price Target: $3 → $4
Current: $7.85
Upside: -49.04%
OptiNose
Nov 7, 2017
Initiates: Outperform
Price Target: $495
Current: $5.00
Upside: +9,800.00%
Teva Pharmaceutical
Aug 4, 2017
Downgrades: Underperform
Price Target: n/a
Current: $20.98
Upside: -
Pacira BioSciences
Apr 13, 2017
Initiates: Outperform
Price Target: $58
Current: $20.55
Upside: +182.24%